SpeeDx is a leading brand in the field of molecular diagnostics, using patented technology to drive innovation in the detection of viral and bacterial infections, as well as antibiotic resistance markers. They offer a wide range of products and services to cater to various diagnostic needs. Their product portfolio includes tests for Sexually Transmitted Infections like Neisseria gonorrhoeae and ciprofloxacin susceptibility, Mycoplasma genitalium and macrolide resistance, as well as Herpes, syphilis, and respiratory infections caused by COVID-19 and other viruses.

They also provide research reagents and accessories for laboratory workflow solutions. One of the key highlights of SpeeDx is their Resistance Guided Therapy (RGT) technology, which helps clinicians make informed treatment decisions by detecting the infecting organism and genetic markers linked to antibiotic susceptibility or resistance. This approach helps improve the likelihood of effective patient treatment, reduce healthcare costs, and limit the spread of antibiotic-resistant infections.

With a dedicated team, innovative solutions, and a commitment to empowering clinicians, SpeeDx is at the forefront of molecular diagnostics, ensuring accurate and efficient diagnostic testing for better patient outcomes